Datavant, the leading health data platform company, and Boehringer Ingelheim have announced a significant expansion of their partnership to advance real-world evidence (RWE) capabilities in pharmaceutical research and development. The collaboration will extend Datavant's privacy-preserving tokenization and data connectivity technologies across 75 additional clinical trials and multiple new molecular entities (NMEs) in Boehringer Ingelheim's pipeline.
The expanded partnership represents a substantial investment in data-driven decision making for clinical development and commercial launch strategies. By implementing these technologies at scale, Boehringer Ingelheim aims to gain deeper insights into patient journeys, treatment effectiveness, and health outcomes.
Secure Data Connectivity Without Compromising Privacy
At the core of this collaboration is Datavant Connect, powered by AWS Clean Rooms, which enables Boehringer Ingelheim to efficiently explore and assess third-party data sources without moving or sharing underlying data. This approach streamlines data discovery, transformation, and linkage processes while maintaining data security within Boehringer Ingelheim's own research environment.
"We are honored to support Boehringer Ingelheim in revolutionizing patient care through a pioneering data strategy," said Arnaub Chatterjee, GM and President, Life Sciences, Ecosystem and Public Sector at Datavant. "By enabling secure and efficient data linkage at scale, Boehringer Ingelheim is setting a new benchmark for medical research. This partnership exemplifies how technology can reshape healthcare and improve patient outcomes."
Accelerating Real-World Data Integration
The implementation of Datavant's technology across Boehringer Ingelheim's broad portfolio aims to accelerate the integration of real-world data into drug development processes. This integration is expected to provide more precise insights into treatment effectiveness, economic impact, and long-term health outcomes.
Paul Petraro, Executive Director and Head of the Real World Evidence Analytics Center of Excellence at Boehringer Ingelheim, emphasized the strategic importance of this initiative: "Our investment in real-world data underscores Boehringer Ingelheim's commitment to using cutting-edge technologies to advance medical research. By expanding this approach across more trials and commercial launches, we are positioned to drive more personalized and cost-effective treatments, ultimately transforming patient care."
Phased Implementation Approach
To ensure seamless integration with existing research infrastructure, the companies will implement tokenization in a phased rollout. This methodical approach aims to establish a robust framework that will guide future studies and demonstrate value to industry peers considering similar real-world evidence strategies based on cloud-first tokenization and data discovery.
The collaboration represents a significant advancement in how pharmaceutical companies can leverage real-world data while maintaining privacy standards. By connecting disparate data sources securely, researchers can develop a more comprehensive understanding of how treatments perform in diverse patient populations outside the controlled environment of clinical trials.
Implications for Drug Development
This expanded partnership has potential implications for accelerating drug development timelines and improving the precision of treatment approaches. Real-world evidence can complement traditional clinical trial data by providing insights into:
- Long-term safety and effectiveness in diverse populations
- Treatment patterns and adherence in clinical practice
- Comparative effectiveness against standard of care
- Economic outcomes and healthcare resource utilization
By incorporating these insights earlier in the development process, Boehringer Ingelheim aims to make more informed decisions about which compounds to advance and how to design trials that address real-world clinical needs.
The collaboration between Datavant and Boehringer Ingelheim demonstrates how technological innovation in data connectivity can address some of the pharmaceutical industry's most pressing challenges in evidence generation while maintaining the highest standards of data privacy and security.
